Janux Therapeutics, Inc. (JANX)

Janux Therapeutics' stock experienced volatility, declining by 68.58% between January 13, 2025, and January 9, 2026. In December 2025, shares fell nearly 50% following an update on Phase 1 interim results for JANX007, leading to lowered price targets and a 52-week low, despite some analysts maintaining "Buy" ratings. A Janux executive sold 16,665 shares for $501,000 in December 2025, and in January 2026, Bank of America Securities maintained a "Buy" rating but lowered its price target for JANX.

Janux Therapeutics does not experience traditional demand seasonality as a clinical-stage biopharmaceutical company. Its revenue is driven by collaborations, licensing agreements, and milestone payments related to its drug development pipeline, rather than seasonal consumer patterns.

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, utilizing its TRACTr and TRACIr platforms to create drugs that activate the immune system to target cancer cells. The company's pipeline includes JANX007 for metastatic castration-resistant prostate cancer, JANX008 for various solid tumors, and JANX009 for HER2-positive cancers. Janux generates revenue through collaborations, licensing agreements, milestone payments, and royalties, including a research collaboration with Merck Sharp & Dohme Corp.

Janux Therapeutics is headquartered in San Diego, California, United States, and its operations primarily involve research, development, and the management of clinical trials.

Janux Therapeutics' brand reputation is characterized by analyst confidence and investor concern following clinical trial updates. Despite a stock drop due to mixed efficacy signals from the JANX007 Phase 1 trial, many analysts maintain "Buy" ratings, citing the drug's potential, and the company benefits from a strategic collaboration with Merck. Concerns about the differentiation of JANX007 and a Grade 5 cardiotoxicity event have led to some "Hold" ratings, reflecting the risks of clinical-stage drug development.

Institutional shareholders hold approximately 75.39% to 108.32% of Janux Therapeutics' stock, with major holders including Ra Capital Management, L.P., Fmr Llc, and Janus Henderson Group Plc. Insiders hold between 29.40% and 62.82% of the company's stock, with Avalon Ventures XI LP being the largest individual shareholder, owning 19.71% of the shares.